Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-08-14
1999-02-16
Jarvis, William R. A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514569, 514570, 514629, A61K 31405, A61K 3119, A61K 3116
Patent
active
058721452
ABSTRACT:
This invention comprises a method of treating migraine in a human comprising co-timely administering of a therapeutically effective amount of a 5-HT agonist coordinated with a therapeutically effective amount of an analgesic, particularly a long-acting NSAID in doses below those ordinarily considered as minimum effective doses as to both 5-HT agonist and long-acting NSAID. Dosage forms are also included herein.
REFERENCES:
patent: 4024279 (1977-05-01), Zor et al.
patent: 4816470 (1989-03-01), Dowle et al.
patent: 5360925 (1994-11-01), Chabrier De Lassauniere et al.
patent: 5387604 (1995-02-01), McDonald et al.
patent: 5514168 (1996-05-01), Friedman
patent: 5605917 (1997-02-01), Ogletree
patent: 5607960 (1997-03-01), Wythes
patent: 5618816 (1997-04-01), Crenshaw et al.
Anderson, "Double-blind study of naproxen vs placebo in the treatment of acute migraine." (1989); Cephalalgia, vol. 9, 29-32.
Baumel, "Migraine: A pharmacological review with newer options and delivery modalities," (1994), Neurology, vol. 44Supp3, S13-S17.
Boureau, "Comparison of subcutaneous sumatriptan with usual acute treatments for migraine. French Sumatriptan Group." (1995) Eur. Neurol., vol. 35(5), 264-269.
Bousser, Efficacy of subcutaneous sumatriptanin the acute treatment of early-morning migraine: a placebo-controlled trial. Early-Morning Sumatriptan Study Group (1993) J Intern Med, vol. 234(2), 211-216.
Cady, "Treatment of Acute Migraine With Subcutaneous Sumatriptan." (1991) JAMA, vol. 265,No. 21, 2831-2835.
Cady, "Efficacy of subcutaneous sumatriptan in repreated episodes of migraine" (1993) Neurology, vol. 43, 1363-1368.
Centonze, "Evaluation of the efficacy of oral sumatriptan in the management of migraine attacks. Clinical Results" (1995) La Clinica Teraputica, vol. 146(11), 721-728 (Article in the Italian language, Citation to English language abstract only at 727).
Dechant, "Sumatriptan A review of its Pharmacodynamic Properties, and Therapeutic Efficacy in the Acute Treatment of Migraine and Cluster Headache" (1992) Drugs, vol. 43(5) 776-798.
Klapper, "Toward a Standard Drug Formulary for the Treatment of Headache" (1995) Headache, Apr., 1995, 225-227.
Oral Sumatriptan Group, "Sumatriptan--An Oral Dose-defining Study" (1991) Eur. Neurol., vol. 31, 300-305.
Thomson, "A Study to Compare Oral Sumatriptan with Oral Aspirin plus Oral Metoclopramide in the Acute Treatment of Migraine" (1992) Eur. Neurol., vol. 32, 177-184.
Todd, "Naproxen A reappraisal of its Pharmacology, and Therapeutic Use in Rheumatic Diseases and pain States" (1990) Drugs, vol. 40(1), 91-137.
Tokola, "Effects of migraine attack and metoclopramide on the absorption of tolfenamic acid" (1984) Br. J Clin. Pharmac, vol. 17, 67-75.
Tokola, "Tolfenamic acid, metoclopramide, caffeine and their combinations in the treatment of migraine attacks" (1984) Cephalalgia, vol. 4, 253-263.
Jarvis William R. A.
Pozen Inc.
LandOfFree
Formulation of 5-HT agonist and NSAID for treatment of migraine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Formulation of 5-HT agonist and NSAID for treatment of migraine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formulation of 5-HT agonist and NSAID for treatment of migraine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2062806